

Independent Grants for Learning & Change (IGLC)
Track 2 - Call for Grant Applications (CGA)
Empower Patients by Enhancing Education, Communication and Decision Aids

I. Background

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. “Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

When a CGA is issued, it is posted on the IGL&C website in the [Grants Process section](#) and is sent via e-mail to all registered users in our grants system. Some CGAs may also be posted on the websites of other relevant organizations.

II. Eligibility

Geographic Scope:	<input checked="" type="checkbox"/> Asia Region: Thailand, Malaysia, Singapore, Hong Kong, Taiwan, India and Philippines
Applicant Eligibility Criteria:	<p>The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.</p> <p>More information on organizations eligible to apply directly for a grant can be found at http://www.pfizer.com/files/IGLC_OrganizationEligibility_effJuly2015.pdf.</p> <p>Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role.</p>

III. Requirements

Date CGA Issued:	[July 15, 2018]
Clinical Area:	Rheumatoid Arthritis
Specific Area of Interest for this CGA:	<p>Rheumatoid arthritis (RA) is a systemic autoimmune disorder in which joints, usually those in the hands and feet, can become inflamed, swollen, painful, and stiff. For patients without appropriate treatment, the inflammation may become chronic and lead to irreversible destruction of bone and cartilage in the affected joints, as well as contribute to the development of clinically important comorbid conditions with attendant morbidity and mortality and lastly impact on the increase in medical costs.</p> <p>Multiple therapies are available for RA management but still there are many patients not on the target. Partly resulting from the level of patients' awareness due to missing the early signs and symptoms of RA, access to healthcare service and improper functioning of the health care system. Gaps that exist for patients include a lack of resources, low health literacy, distance & transportation to access healthcare services, particularly specialist services like rheumatology as well as limitation of health insurance coverage. Consequently, patients with RA come to see rheumatologists at the late stage which lead them to suffer needlessly which can include, disability, job loss and shortened life expectancy.</p> <p>It is our intent to support projects that focus on educating patients on the Treat-to-target concept which promotes effective disease management of rheumatoid arthritis.</p> <p>Projects that focus on education relating to one or more of the following will be considered:</p> <ul style="list-style-type: none"> ▪ Educating patients by increasing awareness of early recognition of disease symptoms to enhance shared decision making between the patient and the caregiver. ▪ Developing a program for patients by rheumatologists or general practitioners (GP) aimed at enhancing and educating patients on how to monitor themselves living with RA <p>*The recommendations and overarching principles guide for treating to target are consisted of a diagnosis of active RA, followed by patients should be assessed using a composite measure of disease activity as frequently as every 1 to 3 months to monitor target achievement (remission or, at the minimum, LDA), and therapy should be adjusted along the way according to disease activity until the target is reached. Lastly, once the target has been attained, patients should be evaluated every 3 to 6 months to ensure that remission (or LDA) are maintained.</p> <p>More information on principles of learning and behavior change for health professionals can be found at www.pfizer.com/files/HealthProfessionalsLearningandBehaviorChange_AFewPrinciples.pdf.</p> <ul style="list-style-type: none"> • Winthrop.K.L. et al. Clin Exp Rheumatol 2016; 34 (Suppl. 98):S69-S76 • Solomon D.H. et al. Arthritis Rheumatol. 2014 Apr; 66(4): 775–782 • Smolen JS, Aletaha D, Bijlsma JW, et al. Ann Rheum Dis. 2010;69:631-37 • Taloy P. C. et al. Rheumatol Int. 2016; 36: 685–695. • Güler Kalem and Çiğdem Turhan / Procedia - Social and Behavioral Sciences 195 (2015) 2014 – 2018 • Doyle-Lindrud S. Clin J Oncol Nurs. 2014 Dec;18(6):634-6 • Baig MM, GholamHosseini H, Connolly MJ. Australas Phys Eng Sci Med. 2015 Mar;38(1):23-38.

Have Expected Approximate Monetary Range of Grant Applications:	Individual projects requesting up to \$100,000 will be considered. The total available budget related to this CGA is \$100,000 . The grant amount Pfizer will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.
Key Dates:	CGA release date: July 15, 2018 Grant application due date: August 27, 2018 Please note the deadline is midnight Eastern Time (New York, GMT -5). Anticipated Grant Award Notification Date: September 24 th , 2018 Grants distributed following execution of fully signed Letter of Agreement Period of Performance: Since grant approval to September 15 or 30, 2019
How to Submit:	Please go to the specific application log-in page and sign in. First-time users should click “REGISTER NOW” . Select the following Educational Area: CGA- Empower Patients by Enhancing Education, Communication and Decision Aids Requirements for submission: Complete all required sections of the online application and upload the completed CGA template (see Appendix). If you encounter any technical difficulties with the grant management system, please click the “Need Support?” link at the bottom of the page. IMPORTANT: Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed by the committee.
Questions:	If you have questions regarding this CGA, please direct them in writing to , Renee Yip , at (Renee.Yip@pfizer.com, with the subject line “[Empower Patients by Enhancing Education, Communication and Decision Aids].”
Mechanism by which Applicants will be Notified:	All applicants will be notified via email by the dates noted above. Applicants may be asked for additional clarification or to make a summary presentation during the review period.

IV. Terms and Conditions

Please take note every Call for Grant Applications (CGA) released by Pfizer Independent Grants for Learning & Change (IGLC) is governed by specific terms and conditions. These terms and conditions can be reviewed here: http://www.pfizer.com/files/PfizerIGLC_CGA_TermsandConditions_2017Nov.pdf

Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a **15-page limit** exclusive of references. Please include the following:

- A. Title
- B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
- C. Goal: Briefly state the overall goal of the project.
- D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
- E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
- F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
- G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.

- H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
- I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
- J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
- K. Timeline
- L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
- M. References (outside the 15-page limit)
- There is no designated format for references
- N. Budget (See template available in application)
- While estimating your budget please keep the following items in mind:
 - Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
 - Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
 - A separate Excel file should be uploaded. This does not count toward the page limit.
 - An example of the budget template can be found here:
<http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls>
 - At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. There is a **15-page limit** exclusive of references. If extensive, references may be included on 1-2 additional pages.